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OBJECTIVE: Anemia, a common chemotherapy complication,
is often treated with erythropoiesis-stimulating agents (ESAs),
DA, EA or EB. The objective of this study was to assess, from a
French societal perspective, the cost consequence of Q3W_DA
administration (500 μg) compared to QW_EA or QW_EB at the
European label doses, based on the results of a European retro-
spective observational study. METHOD: A decision-tree model
making explicit the conduct of the patients in the 16-week obser-
vational study (drug administrations, transfusion and response
to treatment) was developed in Excel®. Transition probabilities,
average Hb value over treatment period, number of blood trans-
fusions and ESA administration settings were extracted from the
observational study. Unit costs were applied to medical resources
used (red blood cells packs, health care professional visits, hos-
pital stays) and to patients’ time, further speciﬁed by a panel of
20 French clinical experts. Time was valued at gross hourly wage
rate. Both time and medical costs were extracted from ofﬁcial
sources (AMELI; INSEE) and adjusted to €2006. A 5000-repli-
cations probabilistic sensitivity analysis was performed with
@RISK® using distributions for probabilities (binomial), medical
resources used (triangular), time (triangular) and outcome mea-
sures (normal). RESULTS: Compared to either EA or EB, DA
showed slightly greater increases in Hb levels (0.128 g/dL [95%
CI: −0.160; 0.411] vs. EA; 0.186 g/dL [−1.995; 0.384] vs. EB)
and a lower cost (€−422 [−920; 42.9] vs. EA; −€114 [95% CI:
−452; 211] vs. EB). Probabilistic sensitivity analysis revealed for
DA_Q3W 80% of the replications vs EA and 73% vs EB with
better Hb values and lower costs (dominant); 3% vs EA and
22% vs EB with higher costs and better Hb values. CONCLU-
SION: This analysis provides real-life information to decision
makers about the costs and consequences of Q3W_DA com-
pared to QW_EA and QW_EB. A decision in favor of Q3W_DA
has the highest probability to be beneﬁcial from a health eco-
nomic viewpoint.
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OBJECTIVES: Study aim was to compare symptom severity and
home assistance burden in advanced non-small-cell-lung cancer
(NSCLC) patients with no metastasis (NM), bony and/or cere-
bral (BCM) metastases and other metastasis localization (OM).
METHODS: A total of 104 advanced NSCLC patients were
enrolled in 18 Italian oncology departments and followed up for
3 months. Main caregiver workload was assessed monthly by a
task scale; activities of other caregivers were also registered and
patients completed the LCS symptoms subscale of the FACT-L
questionnaire. Formal caregiving time was valued according to
market prices; informal caregiving hours were valued using the
wage rate for an equivalent service. RESULTS: Mean age of the
total sample was 65.5 years, males’ prevalence of was over 80%;
principal caregiver was patient’s spouse living with the patient
and non-working in over 70% of cases. Three-monthly mean
total per patient assistance costs amounted to €4431 in BCM, to
€2617 and €2716 in OM and NM patients. Cerebral and/or
bony metastases caused, upon each monthly check, signiﬁcantly
higher assistance costs referred to the main caregiver (p <
0.0001). Higher percentages of patients reported symptoms dete-
rioration in the NM and BCM (45% and 43%) respectively,
while only 23% of patients referred symptom worsening in OM.
CONCLUSION: Home assistance burden was higher in patient
with bony and/or cerebral metastases, other metastasis localiza-
tions showed no impact on caregiving costs and symptom sever-
ity measured by the LCS subscale.
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OBJECTIVE: The incidence of renal cell carcinoma (RCC) in
Spain is about 4000 patients per year. RCC patients have limited
treatment options and low survival rates at 5 years in advanced-
staged patients. Despite the growing importance of RCC, data
on its economic burden are limited. METHODS: An incidence-
based approach was used to estimate the aggregate annual cost
burden from a societal perspective, including costs of medical
treatment and lost productivity due to RCC in Spain. The annual
numbers of patients treated for RCC were classiﬁed by age,
gender and cancer stage (I–IV). The utilization of cancer speciﬁc
treatments, unit costs of these treatments, work-days missed by
these patients and wage rates were included in the model. Data
source included the linked Surveillance, Epidemiology, and End-
results. Data were obtain from publishes literature and experts’
opinion. RESULTS: The annual cost of RCC in Spain (€ 2005)
was found to be €41.8 million (€10,607 per patient). Health-care
costs and lost productivity accounted for 66.3% (€27.8 million)
and 33.7% (€14.1 million) of the total cost, respectively. The
total cost associated with RCC stage II accounted for the highest
portion (43.4%) of the total cost of illness, at €18.2 million. This
reﬂected the highest incidence of RCC at stage II (54% of all
incident cases). Other stages (I, III and IV) accounted for 11.1%
(€4.6 million), 12.1% (€5.1 million) and 33.4% (€14.0 million)
of the overall cost. Per patient cost was remarkably high for stage
IV patients (€17.748), attributable to the high resource utiliza-
tion for this stage. CONCLUSIONS: The economic impact of
RCC in Spain is substantial. New therapies for RCC have the
potential to yield considerable economic and social beneﬁts.
PCN36
BURDEN OF CERVICAL CANCER IN POLAND
Kawalec P1, Glogowski C2, Krzyzanowska A3
1Centrum HTA, Krakow, Poland, 2GSK Commercial Sp. z o.o, Warsaw,
Poland, 3GlaxoSmithKline Poland, Warsaw, Poland
OBJECTIVES: To assess the costs of cervical cancer in Poland
in 2006 measured from the public payer or the societal perspec-
tive. METHODS: The time horizon of the analysis was 12
months and a retrospective approach based on Polish oncology
register was applied. Calculations were performed from the
public payer (direct costs) or societal perspectives (both direct
and indirect costs). Direct medical costs cover diagnostic tests,
surgery, physician consultations and rehabilitation; the unit costs
were obtained from the Polish National Health Fund. Costs from
societal perspective including both costs from public payer point
of view and productivity loss for each clinical state were calcu-
lated on Polish ofﬁcial statistical data; both sick-leave and pre-
mature mortality were taken into account. Number of invasive
